Diabetic Foot and Venous Leg Ulcers Treated With BioLab’s Amnion-Based Products to Be Studied in BIOCAMP

August 12, 2025—BioLab Holdings, Inc., recently announced the initiation of the BIOCAMP study assessing the company’s human placental membrane (HPM) products in the management of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The minimally manipulated allografts are derived from human amniotic membrane and designed to preserve the tissue’s natural properties and support healing, stated the company.

According to BioLab, the multicenter, prospective, randomized controlled study will evaluate the efficacy of four HPM products in combination with standard of care (SOC) compared to SOC alone in the treatment of nonhealing DFUs and VLUs.

As outlined in the company’s press release, BIOCAMP will enroll 650 patients at up to 30 clinical sites nationwide. Patients will be randomized to receive one of four BioLab products—Tri-Membrane Wrap (HPM-1), Membrane Wrap (HPM-2), Membrane Wrap-Lite (HPM-3), or Membrane Wrap-Hydro (HPM-4)—in addition to SOC, or SOC alone.

Treatments will be applied weekly for up to 12 weeks or until complete wound closure is achieved and confirmed 2 weeks later. Optional weekly visits will allow for dressing changes in both study arms, noted the press release.

The company stated that BIOCAMP is its most comprehensive clinical trial to date and is designed to capture real-world clinical outcomes and support the growing body of evidence for the use of placental-derived allografts in chronic wound management.

In July, BioLab announced the launch of AMNIOHEAL RWE, a multicenter, hybrid platform trial evaluating the clinical real-world effectiveness of its amnion-based Tri-Membrane Wrap and Membrane Wrap-Lite wound care products in patients with DFU and VLUs.